Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 16, 2014 (12 years ago)

Labetalol Hydrochloride Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulate Matter; metal embedded in the glass vial and visible particles floating in the solution

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Labetalol Hydrochloride Injection, USP, 100 mg/20 mL (5 mg/mL), 20 mL Multidose Vial, packaged 50/20 mL glass vials/carton, Hospira, Inc., Lake Forest, IL 60045 --- NDC 0409-2267-20

Affected NDC 0409-2267-20

Compare with the code on your package — it is the most precise check available.

Drug: Labetalol

Recalling firm
Hospira Inc.
NDC code
0409-2267-20
Origin
IL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1424-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Labetalol recalls

See all
Class II · Moderate risk

PF-Labetalol HCl Injection

CGMP Deviations: Potential for cross contamination due to product carry over.

Terminated Cross-contamination Nephron Sterile Compounding Center LLC NDC 69374-946-34 D-0064-2023
Class II · Moderate risk

PF-Labetalol HCl Injection

CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.

Terminated Cross-contamination Nephron Sterile Compounding Center LLC NDC 69374-946-34 D-1347-2022

Other recalls by Hospira Inc.

All 2014 recalls
Class II · Moderate risk

DOBUTamine Injection

Discoloration: Firm received complaints of product discoloration and particulates.

Terminated Failed specification Hospira Inc. NDC 0409-2025-20 D-1500-2016